PCSA
Processa Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$2.22-3.90%
Price as of Jul 20, 2026
PCSA growth
Processa Pharmaceuticals, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -16.8%
- EBIT
- -19.7%
- EPS
- +86.3%
- Free cash flow
- -2.7%
- Operating cash flow
- -2.7%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +83.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -14.5%
- EBIT
- -16.1%
- Net income
- -14.5%
- EPS
- +89.3%
- Free cash flow
- -1.2%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.